Ekso Bionics Holdings reported its financial results for the three and six months ended June 30.
Highlights included:
- Reported revenues of $5 million in the second quarter (2Q)
- Initial Medicare claims for Ekso Indego Personal are currently pending reimbursement
- Achieved gross margin of 53 percent in 2Q
- Gross profit was $2.6 million, compared to $2.3 million for 2Q 2023. The increase in gross margin was primarily due to an increase in the average selling price for the EksoNR and lower EksoHealth device and service costs.
- Revenue was $8.7 million for the six months ended June 30, compared to $8.8 million for the same period in 2023.
- The company sold 66 EksoHealth devices in the first half of 2024.
- Gross profit for the six months ended June 30 was $4.6 million, representing a gross margin of approximately 53 percent, compared to gross profit of $4.3 million for the same period in 2023, representing a gross margin of 48 percent.
- Net loss applicable to common stockholders for the six months ended June 30 was $5.8 million, or $0.33 per basic and diluted share, compared to net loss of $8.6 million, or $0.64 per basic and diluted share, for the same period in 2023.
- Cash on hand at June 30 was $5.9 million, compared to $8.6 million at December 31, 2023.
